On Monday, Shares of SunCoke Energy Inc (NYSE:SXC), lost -28.10% to $7.01. The stock attained the volume of 4.02 million shares.
SunCoke Energy Partners, L.P. stated third quarter 2015 net income attributable to SXCP of $19.5 million as contrast to $20.2 million in the same preceding year period. The quarter’s results reflect the Granite City cokemaking facility dropdown and Convent Marine Terminal transactions, offset by higher financing costs and the impact of the idling of our customer’s facility, Haverhill Chemicals LLC, with whom we have a steam supply agreement.
THIRD QUARTER RESULTS
(1) Comprises 100 percent of Granite City in third quarter 2015 and 2014.
(2) See definition of Adjusted EBITDA and reconciliation elsewhere in this release.
(3) Net income attributable to SXCP comprises the impacts of SXCP’s 75 percent ownership interest in Granite City from July 1, 2015 through August 11, 2015 and SXCP’s 98 percent ownership interest in Granite City from August 12, 2015 through September 30, 2015, respectively.
Revenues were $210.2 million in third quarter 2015, a decline of $6.6 million from the same preceding year period primarily due to the pass-through of lower coal costs in our Domestic Coke segment, partially offset by revenue generated by our new Convent Marine Terminal.
SunCoke Energy, Inc. operates as an independent producer of coke in the Americas. The company offers metallurgical and thermal coal for use as a raw material in the blast furnace steelmaking process.
Shares of Biogen Inc (NASDAQ:BIIB), dropped -1.67% to $264.67, during its last trading session.
The stock saw its price movement on above -normal volume, as 3.68 million shares changed hands when contrast with its average daily volume of 2.98 million shares, with a year-to-date performance of -22.03%.
Shares of Biogen (BIIB) have earned a consensus recommendation of “Buy” from the twenty-six ratings firms that are covering the firm, Analyst Ratings Network.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, fifteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $410.92.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally.
Finally, E I Du Pont De Nemours And Co (NYSE:DD), ended its last trade with -0.93% loss, and closed at $55.66.
If guitars, piano and voice shape music; and email, texts and blogs shape how we communicate; then nylon shapes ideas.
Now celebrating its 80th anniversary, the breakthrough material invented by DuPont Researcher Wallace Carothers in 1935 is credited for making many consumer goods — stockings, toothbrushes, hand-held devices — more affordable, attractive and accessible to everyone around the world. The lightweight material is frequently used to replace metal, lowering weight and cost and inviting design freedom and parts integration.
Nylon’s versatility and strength, backed by science to coax out added performance and a global development network to support customers, proved to be the formula that earned nylon its reputation and its place as one of DuPont’s most successful products.
DuPont pioneered the science that transformed nylon fiber into an engineering polymer in the 1940s. Its exponential growth in that decade is in part credited to the U.S. government, which advised replacing metal with plastics wherever possible to support the war effort. Bottles, cups, even car parts were made lighter and more affordable during this decade.
E I. du Pont de Nemours and Company operates as a science and technology based company worldwide. The company’s Agriculture segment offers corn hybrid, soybean, canola, sunflower, sorghum, inoculants, seed products, wheat, rice, herbicides, fungicides, and insecticides.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
